The loss per share is an accounting artifact: $632.2 million of acquired in-process R&D from the iRenix and Alkeus deals ran straight through the income statement. Underneath it, XDEMVY sales grew about 64% year over year, exceeding expectations on revenue. Management points to five medicines in five years, with no formal guidance.
Latest Activity
TARS Coverage
QQQ Crash: Live Updates on Amazon (AMZN), Meta, Apple (AAPL) Following Today’s Selloff
Live Updates DeepSeek Isn’t the Only Reason for a Big Drop in Tech Stocks2:06pm ETThe markets continue to bounce around in afternoon trading. The Invesco QQQ Trust (NASDAQ:QQQ) is down 3.3%, up…